Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 44

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 44
---
 copies of any such notice that the Company reasonably believes constitutes material
non-public information and the Company would not be required to publicly disclose such notice in any report or statement filed with the
SEC and under the Exchange Act or the Securities Act. Notwithstanding the foregoing, the requirements of this Section 5(c) shall be satisfied
to the extent that the contents of such notice are made available through a document filed by the Company with the SEC and available on
the SEC’s EDGAR system (or any successor thereto) within the required time period. The Company shall pay all fees and expenses in
connection with satisfying its obligations under this . The Company shall take commercially reasonable actions necessary
to ensure that its Depositary Shares can be transferred electronically as DWAC Shares.

| -22- |

(d) . The Investor agrees that beginning on the date of this Agreement and
ending on the date of that is one Business Day following the termination of this Agreement as provided in Section 11, the Investor and
its agents, representatives and affiliates, including any entity managed or controlled by the Investor shall not, directly or indirectly,
in any manner whatsoever (i) enter into or effect, directly or indirectly, any (x) “short sale” (as such term is defined in
Rule 200 of Regulation SHO of the Exchange Act) of the Depositary Shares or (y) hedging transaction, which establishes a net short position
with respect to the Depositary Shares or (ii) be in violation of Regulation SHO. In addition to the foregoing, in connection with any
sale of Securities, the Investor shall comply in all respects with all applicable laws, rules, regulations and orders, including, without
limitation, the requirements of the Securities Act and the Exchange Act.

(e) . In consideration for the Investor’s execution and delivery of this Agreement, the Investor shall be entitled to receive
a fee of $875,000 (equaling 2.5% of the Available Amount) in cash in immediately available funds to an account designated by the Investor,
which amount shall be due and payable on the Execution Date, as a commitment fee (the “”), of which (i)
1.75% of the Available Amount ($612,500) shall be paid to the Investor on the Execution Date (the “”)
and (ii) the balance of such Commitment Fee shall by paid to the Investor, in a pro rata fashion, simultaneously with the delivery of
any and all Purchase Shares purchased under this Agreement under